Last update 20 Mar 2025

Multi-target Gene-modified CAR-T/TCR-T Cell (Shenzhen Binde Biotechnology )

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms-
Target
BCMA x CD19 x CD22 x CD33 x CD38 x DR5 x EGFRvIII x MSLN x NY-ESO-1 x c-Met
Action
inhibitors, modulators, antagonists
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors)
+ [7]
Therapeutic Areas
NeoplasmsImmune System DiseasesNervous System Diseases+ [8]
Active Indication-
Inactive Indication
CD19-positive B-cell acute lymphoblastic leukemiaColorectal CancerEsophageal Carcinoma+ [12]
Originator Organization
Shenzhen Binde Biotechnology Co., Ltd.Shenzhen Binde Biotechnology Co., Ltd.
Active Organization-
Inactive Organization-
Drug Highest PhasePendingPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Multi-target Gene-modified CAR-T/TCR-T Cell (Shenzhen Binde Biotechnology )
NCT03638206
/ Unknown statusPhase 1/2
Autologous Immunotherapy With Multi-target Gene-modified CAR-T/TCR-T Cell for Malignancies
100 Clinical Results associated with Multi-target Gene-modified CAR-T/TCR-T Cell (Shenzhen Binde Biotechnology )
Login to view more data
100 Translational Medicine associated with Multi-target Gene-modified CAR-T/TCR-T Cell (Shenzhen Binde Biotechnology )
Login to view more data
100 Patents (Medical) associated with Multi-target Gene-modified CAR-T/TCR-T Cell (Shenzhen Binde Biotechnology )
Login to view more data
100 Deals associated with Multi-target Gene-modified CAR-T/TCR-T Cell (Shenzhen Binde Biotechnology )
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD19-positive B-cell acute lymphoblastic leukemiaPhase 2
China
-01 Mar 2018
Colorectal CancerPhase 2
China
-01 Mar 2018
Esophageal CarcinomaPhase 2
China
-01 Mar 2018
Hepatocellular CarcinomaPhase 2
China
-01 Mar 2018
MesotheliomaPhase 2
China
-01 Mar 2018
Multiple MyelomaPhase 2
China
-01 Mar 2018
Myeloid LeukemiaPhase 2
China
-01 Mar 2018
Pancreatic CancerPhase 2
China
-01 Mar 2018
Stomach CancerPhase 2
China
-01 Mar 2018
Synovial SarcomaPhase 2
China
-01 Mar 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free